#USA #New York #Class Action #Sana Biotechnology #Levi Korsinsky

Overview of the Sana Biotechnology Class Action Lawsuit

Levi & Korsinsky, LLP, a prominent law firm known for its securities litigation, has issued a crucial reminder to investors in Sana Biotechnology, Inc. about a lead plaintiff application deadline in a class action lawsuit. This legal case centers around allegations of securities fraud that potentially impacted investors between March 17, 2023, and November 4, 2024. Stakeholders who incurred losses during this period should be particularly aware of their rights and opportunities for recourse.

Class Action Details

The class action has been filed to recover losses for investors who believe they were misled by Sana Biotechnology's management regarding the company's finances and viability of certain product candidates. According to the lawsuit, there were several misleading statements made by the defendants, implying a stronger operational and financial position than what was actually the case.

Specifically, the complaint alleges that:

• - Sana was at risk of not having enough funds to sustain its operations and further develop its products.
• - The advancement of key product candidates, including SC291 in oncology, SC379, and SG299, was not as promising as claimed by the firm's representatives.
• - To preserve cash for more viable projects, the company might decrease funding or even discontinue some products and significantly reduce its workforce.

These claims suggest that the false statements made significantly overstated Sana's financial ability to conduct ongoing operations and develop existing solutions, painting a misleading picture for investors.

Next Steps for Investors

Investors who suffered financial losses linked to Sana Biotechnology during the alleged fraudulent period have until May 20, 2025, to file their lead plaintiff applications. It is important to note that being a lead plaintiff is not a requirement for any potential recovery; investors still have the option to benefit without participating directly in the litigation leadership.

No Cost to Participate

One of the most reassuring aspects of this class action is that participating investors may qualify for compensation without spending any out-of-pocket money. There are no charges or obligations associated with joining the action, making it an accessible avenue for potential recovery.

Experience of Levi & Korsinsky

The law firm Levi & Korsinsky has been a notable player in securities litigation for over 20 years, having secured substantial settlements for aggrieved investors. Their track record includes being recognized in the ISS Securities Class Action Services' Top 50 Report as one of the leading securities litigation firms in the United States for seven consecutive years. This experience presents a solid assurance for potential plaintiffs in the Sana case.

Contact Information

Investors looking for more information can reach out to Levi & Korsinsky directly. Contact Joseph E. Levi, Esq. or Ed Korsinsky, Esq. at their New York office:

• - Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
• - Email: [email protected]
• - Phone: (212) 363-7500

Investors are encouraged to act promptly, given the upcoming deadline and potential benefits from participating in the lawsuit. It's vital to stay informed and proactive about options available after experiencing financial losses in the unpredictable landscape of biotechnology investments.